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ABSTRACT 
Background: We evaluated the associations of anthropometric indicators of general obesity (body mass 
index, BMI), an established risk factor of various cancer, and body fat distribution (waist circumference, 
WC; hip circumference, HC; and waist-to-hip ratio, WHR), which may better reflect metabolic 
complications of obesity, with total obesity-related and site-specific (colorectal and postmenopausal 
breast) cancer incidence.  
Methods: This is a meta-analysis of seven prospective cohort studies participating in the CHANCES 
consortium including 18,668 men and 24,751 women with a mean age of 62 and 63 years respectively. 
Harmonized individual participant data from all seven cohorts were analysed separately and alternatively 
for each anthropometric indicator using multivariable Cox proportional hazards models.  
Results: After a median follow-up period of 12 years, 1,656 first incident obesity-related cancers [defined 
as postmenopausal female breast, colorectum, lower oesophagus, cardia stomach, liver, gallbladder, 
pancreas, endometrium, ovary, and kidney] had occurred in men and women. In the meta-analysis of all 
studies, associations between indicators of adiposity, per standard deviation (SD) increment, and risk for 
all obesity-related cancers combined yielded the following summary hazard ratios: 1.11 (95 % CI 1.02-
1.21) for BMI, 1.13 (95 % CI 1.04-1.23) for WC, 1.09 (95 % CI 0.98-1.21) for HC, and 1.15 (95 % CI 
1.00-1.32) for WHR. Increases in risk for colorectal cancer were 16%, 21%, 15%, and 20%, respectively 
per SD of BMI, WC, HC, and WHR. Effect modification by hormone therapy (HT) use was observed for 
postmenopausal breast cancer (P-interaction<0.001), where never HT users showed an approximately 20% 
increased risk per SD of BMI, WC, and HC compared to ever users. 
Conclusions: BMI, WC, HC, and WHR show comparable positive associations with obesity-related 
cancers combined and with colorectal cancer in older adults. For postmenopausal breast cancer we report 
evidence for effect modification by HT use. 
 
Keywords: CHANCES consortium; Ageing; Cohort; Obesity; Body fat distribution, Cancer; Prevention 
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INTRODUCTION 1 
The proportion of overweight (body mass index, BMI>25 kg/m2) or obese (BMI>30 kg/m2) 2 
adults worldwide increased substantially between 1980 and 2013 (NCD Risk Factor Collaboration, 2016), 3 
with parallel increases in children and adolescents (Ng et al, 2014). Obesity prevalence reaches its peak 4 
between age 55 and 60 years in men with ~25% being obese in high-income countries and about 5 years 5 
later in women with ~30% being obese (Ng et al, 2014). This may have substantial implications for risk 6 
of subsequent cancer development, particularly in older adults (60+ years) considering that they are the 7 
fastest growing demographic group in most high-income countries.  8 
It is well established that a high BMI is associated with an increased risk of a large number of 9 
non-communicable diseases, including cancer. Excess body fatness, as defined by high BMI, has been 10 
convincingly linked to an increased risk of eleven different cancer types, including cancer of the 11 
oesophagus (adenocarcinoma), gastric cardia, colorectum (CRC, colorectal cancer), gallbladder, pancreas, 12 
liver, breast (postmenopausal), ovary, endometrium, kidney and prostate (advanced stage) (World Cancer 13 
Research Fund / American Institute for Cancer Research, 2007; Renehan et al, 2008; Bhaskaran et al, 14 
2014). An up-dated IARC consensus review also judged the strength of evidence sufficient for thyroid, 15 
meningioma, and multiple myeloma (Lauby-Secretan et al, 2016). These cancers alone  comprise about 16 
50% of the total global burden of cancer (based on GLOBOCAN 2012 data) (Arnold et al, 2016b). 17 
However, there are uncertainties with regard to how well BMI captures the complex biology 18 
underlying associations between adiposity and cancer risk (Renehan et al, 2015). This is relevant to the 19 
development of cancer prevention strategies because it is increasingly recognized that a proportion of 20 
overweight or obese individuals – as defined by a high BMI – might not be at an increased risk for 21 
metabolic complications of obesity and its consequences such as cancer (Renehan et al, 2015). Waist 22 
circumference (WC) and waist-to-hip ratio (WHR) are therefore often used in epidemiological and 23 
clinical settings as a means of quantifying body fat distribution indicating central adiposity (National 24 
Heart, Lung, 1998; Hu, 2008), and they are thought to be superior predictors of risk of cancer 25 
development, at least for the colon and postmenopausal breast (Moore et al, 2004; Pischon et al, 2006; 26 
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White et al, 2015). Moreover, a greater hip circumference (HC), after controlling for WC and/or BMI, 27 
may be associated with reduced risks of coronary heart disease, type 2 diabetes, and mortality (Heitmann 28 
& Lissner, 2011; Cameron et al, 2013), but its relation to cancer risk has been fully explored in only a few 29 
recent studies (Keimling et al, 2013; Steffen et al, 2015), where either no association was found for risk 30 
of colon cancer with and without adjustment for BMI (Keimling et al, 2013) or inverse associations with 31 
risk of oesophageal adenocarcinoma after adjustment for WC (Steffen et al, 2015). Strictly speaking, HC 32 
is not a measure of central adiposity, but of fat accumulated in the lower part of the body (such as the hips 33 
and thighs) (Hu, 2008). Together, the evidence that measures of body fat distribution or central adiposity 34 
are better predictors of cancer risk than BMI is inconsistent. Also, only a few prospective studies 35 
comparing different measures of adiposity were carried out in adults aged 60 years and above.  36 
Our primary objective was to derive standardized risk estimates for anthropometric measures of 37 
general adiposity (BMI) and body fat distribution (WC, HC, and WHR) and their association with 38 
‘obesity-related’ cancers combined (i.e. cancer sites with convincing evidence of a positive association 39 
with greater body fatness) as well as CRC and (postmenopausal) breast cancer in a large population of 40 
older adults from Europe. Secondary objectives were to examine the shape of the dose–response 41 
relationships and to evaluate potential effect modification by sex, smoking status, use of hormone therapy 42 
(HT), and interaction between measures of body fat distribution and general adiposity.  43 
 44 
METHODS 45 
Study population. The Consortium on Health and Ageing: Network of Cohorts in Europe and the 46 
United States (CHANCES) project (www.chancesfp7.eu) is a multi-country study which aims to 47 
harmonize data from ongoing prospective cohort studies in Europe and North-America (Boffetta et al, 48 
2014).  49 
The following CHANCES cohorts provided data for the current analysis: the study centers in 50 
Denmark, Greece, the Netherlands, and Spain of EPIC-Elderly, which is a subset of the European 51 
Prospective Investigation into Cancer and Nutrition (EPIC) project that consists of participants aged 60 52 
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years or older at recruitment; the Epidemiological Study on Chances for Prevention, Early Detection, and 53 
Optimized THERapy of Chronic Diseases at Old Age (ESTHER), a population-based cohort covering the 54 
entire federal state of Saarland in Germany, aged 50 or older at recruitment; the PRIME Belfast study, 55 
which is a cohort of male residents aged 50-60 years of Belfast and the surrounding area in the United 56 
Kingdom; and the Tromsø study, which recruited men and women in Norway between 1994 and 1995 (4th 57 
wave) aged 50-84 years. Other CHANCES cohorts either decided not to participate in this analysis or 58 
could not provide cancer incidence data. The participating cohorts’ key characteristics are summarized in 59 
Table 1. Additional information on the individual cohorts has been given previously (Boffetta et al, 60 
2014). We followed similar inclusion and exclusion criteria, which are displayed in Figure 1, as in a 61 
companion paper on overweight duration and risk of cancer (Arnold et al, 2016a). Further to the 62 
exclusions shown in Figure 1, we excluded participants with an implausible BMI below 15 or above 45 63 
kg/m2 from the analysis.  64 
All CHANCES cohort studies are conducted in accordance with the Declaration of Helsinki. For 65 
each study, investigators satisﬁed the local requirements for ethical research, including obtaining 66 
informed consent from participants. 67 
 68 
Outcomes. Incident cancer cases were identified through linkage to cancer registries (EPIC 69 
Netherlands, EPIC Denmark, Tromsø) or through self-reports that were confirmed by medical records 70 
and/or pathology reports (ESTHER, PRIME Belfast) or both (EPIC Spain, EPIC Greece). All analyses 71 
were conducted for cancer sites with convincing evidence of a positive association with greater body 72 
fatness (World Cancer Research Fund / American Institute for Cancer Research, 2007; Renehan et al, 73 
2008; Lauby-Secretan et al, 2016). We examined first invasive breast cancer (ICD-O-3 C50) at 74 
postmenopausal ages, CRC (C18-21), and the combination of the two in conjunction with ‘other obesity-75 
related cancers’ that included cancer of the lower oesophagus (C15.5, as a proxy for oesophageal 76 
adenocarcinoma in the absence of histological data), gastric cardia (C16.0), liver (C22), gallbladder 77 
(C23), pancreas (C25), endometrium (C54), ovary (C56) and kidney (C64), together labeled as ‘obesity-78 
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related cancers’. Advanced prostate cancer was not included because we lacked information on tumor 79 
stage. Also, thyroid, meningioma, and multiple myeloma (Lauby-Secretan et al, 2016) were not included 80 
due to very small numbers of incident cases and inconsistencies in the available data across cohorts. 81 
Small numbers precluded the possibility of performing separate analyses of each obesity-related cancer 82 
site. 83 
 84 
Anthropometric assessment. In all cohorts except ESTHER, height and weight were measured by 85 
trained personnel at baseline. In the ESTHER cohort, height and weight were self-reported by the study 86 
participants.  87 
Waist and hip circumference were measured by trained personnel in all cohorts except ESTHER, 88 
where these measures were not assessed; the narrowest torso circumference (natural waist) or midway 89 
between the lowest rib and iliac crest was used for the waist measurement, while the widest 90 
circumference or maximum circumference over the buttocks was used for the hip measurement. The 91 
majority of cohorts reported that participants were asked to remove any heavy outer garments (light 92 
clothing or underwear only allowed) for the anthropometric measurements. In ESTHER, data on WC or 93 
HC were not collected at baseline.  94 
 95 
Covariate assessment. Age, sex, smoking status, physical activity, alcohol consumption, and HT 96 
use in women were collected in all cohorts following standardized procedures and a posteriori 97 
harmonized within the CHANCES project (Boffetta et al, 2014). All covariates except alcohol 98 
consumption (continuous, g/day) were modelled categorically: (daily) smoking status (never daily 99 
smoker; former daily smoker; current daily smoker; unknown), (vigorous) physical activity (yes; no; 100 
unknown) defined according to the CHANCES harmonization rules as ‘performing intense exercise at 101 
least once a week’, level of education attained (primary or less; more than primary but less than college or 102 
university; college or university; unknown), current use (or history) of HT in women (ever; never; 103 
unknown).  104 
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Statistical analysis. Cox proportional hazard models with age as the time metric were used to 105 
estimate hazard ratios (HR) and 95% confidence intervals (CI) for the relation between four obesity 106 
indicators and the risk of developing (1) ‘obesity-related cancers’, (2) CRC, (3) postmenopausal breast 107 
cancer, and (4) ‘other obesity-related cancers’ in each of the included cohorts. All obesity indicators were 108 
treated as continuous covariates; BMI was examined as a measure of overall adiposity, whereas WC, HC, 109 
and WHR were examined as measures of body fat distribution. For comparability between the four 110 
obesity indicators, we calculated the HR and their CI per 1-standard deviation (SD) increment of each 111 
indicator (Keimling et al, 2013). The relationships between anthropometric measures were evaluated 112 
using Pearson correlation coefficients (Supplementary Table S1). 113 
Subjects were censored at age of study exit (death, lost to follow-up, any cancer diagnosis other 114 
than cancers considered as outcomes in this study, and end of follow-up), whichever occurred first.  115 
For all outcomes, three models with different sets of adjustments were fitted. Model 1 included 116 
each of the anthropometric measures alternatively, stratified by age (1-y categories) and sex, and adjusted 117 
for height (except the model for BMI). Model 2 (main model) extended Model 1 by further adjusting for 118 
smoking status, alcohol consumption, level of educational attainment, physical activity, and recruitment 119 
year. Missing values in any of the categorical covariates were included as a separate category. Model 3 120 
was based as model 2, but with mutual adjustment for all anthropometric measures using residuals of 121 
WC, HC, and WHR (Roswall et al, 2014).  122 
All Cox models were fitted for each study separately (EPIC-Elderly was sub-divided into study-123 
centers/countries) giving a study-level risk per 1-SD increment and the results of models 2 and 3 were 124 
then combined using DerSimonian and Laird random-effect meta-analysis (Harris et al, 2008). The 125 
heterogeneity of associations across studies was expressed by I2 (Higgins & Thompson, 2002).  126 
The proportional hazard assumptions in the study-specific analysis were assessed by visual 127 
inspection of log-log plots and by statistical tests using Schoenfeld residuals. Because the proportional 128 
hazards were unlikely for sex and age, we stratified Cox models by sex and age (in 1-y categories). 129 
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Exclusion of individuals with missing data on smoking, education or physical activity gave virtually the 130 
same results. 131 
To directly compare cancer risk discrimination between the four obesity indicators, we used 132 
respective predictions from Cox models (model 2, pooling all cohorts) to assess discrimination by 133 
Harrell’s C-index (Collaboration TFS, 2009). 134 
For analyses addressing the impact of effect modification, we pooled all cohorts into one dataset, 135 
and additionally stratified all Cox models by study. To investigate potential non-linear dose-response 136 
associations between the four obesity indicators and cancer risks, we used three-knot restricted cubic 137 
spline models at Harrell’s default percentiles (i.e. 10th, 50th, and 90th) in combination with a Wald-type 138 
test to evaluate the linearity hypothesis (Orsini & Greenland, 2011). 139 
We tested a priori for potential interactions between the four adiposity indicators and for effect 140 
modification of the studied associations by smoking status and HT use using likelihood ratio tests. Since 141 
Cox-models were stratified by sex and age, no formal tests for interaction by sex or age were performed. 142 
All statistical tests were two-sided and P-values were considered statistically significant at the 143 
0.05 level. All statistical analyses were performed using Stata 12.1 (College Station, Texas, USA). 144 
 145 
RESULTS 146 
In total, 43,419 participants were included in this study, with 1,656 obesity-related cancer cases 147 
occurring during a median follow-up time of 12 years, which ranged between 10.4 years in Germany 148 
(ESTHER) and 18.0 years in Northern Ireland (PRIME Belfast) (Table 1). Study participants were 149 
recruited between 1991 and 2003, with a mean age at study entry ranging from 54 years in Northern 150 
Ireland to 67 years in Greece (EPIC-Greece). The prevalence of obesity (BMI>30 kg/m2) at recruitment 151 
was lowest in Northern Ireland with 11% and highest in participants from Spain with 42%.  152 
 153 
Meta-analysis of adiposity measures and risk of cancer. In the meta-analysis of all studies, BMI, 154 
WC, and WHR were significantly associated with an increased risk of ‘obesity-related cancers’; the HRs 155 
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per 1-SD increment in BMI, WC, and WHR were 1.11 (95% CI: 1.02-1.21), 1.13 (95% CI: 1.04-1.23), 156 
and 1.15 (95% CI: 1.00-1.32), respectively. For BMI, the risk was most pronounced in the PRIME Belfast 157 
study (HR=1.50, 95% CI: 1.08-2.07) and a statistically non-significant inverse association was observed 158 
in the EPIC-Spain cohort (HR=0.88, 95% CI: 0.74-1.04) (Figure 2). After adjusting for HC and WC 159 
(Model 3 – Supplementary Figure S1), the HR for EPIC-Spain per 1-SD increase in BMI changed to 1.14 160 
(95% CI: 0.82-1.60) and heterogeneity across studies for BMI decreased from 59% (P-heterogeneity=0.02) to 161 
<1% (P-heterogeneity=0.58). Omitting EPIC-Spain from the meta-analysis also reduced heterogeneity for 162 
BMI (to 25%, P-heterogeneity=0.25) and for HC (61% to 7%, P-heterogeneity=0.369). HC was positively 163 
associated with risk of ‘obesity-related cancers’ with a comparable effect size (HR1-SD increase=1.09, 95% 164 
CI: 0.98-1.21) but did not reach formal statistical significance (Figure 2). Mutual adjustment for adiposity 165 
measures attenuated risk estimates for all measures of body fat distribution, i.e. WC, WHR, and HC. In 166 
contrast, the HR for BMI increased to 1.15 per 1-SD increment and remained statistically significant 167 
(95% CI: 1.09-1.22) (Model 3 – Figure S1). 168 
For CRC, findings were more consistent across the four adiposity measures with little evidence 169 
for heterogeneity across studies (all I2<36%, all P-heterogeneity>0.17), although the risk estimates for EPIC-170 
Spain followed a similar pattern as for ‘obesity-related cancers’ (Figure 3) including reduced 171 
heterogeneity after omitting EPIC-Spain (data not shown). Effect sizes for CRC were in general higher 172 
with strongest associations observed for WC (HR1-SD increase=1.21, 95% CI: 1.08-1.35) and the weakest for 173 
HC (HR1-SD increase=1.15, 95% CI: 1.01-1.32). After mutual adjustment for adiposity measures, only BMI 174 
remained a significant risk factor of CRC (HR1-SD increase=1.19, 95% CI: 1.08-1.31) (Figure S1).  175 
For postmenopausal breast cancer, a significant positive association was observed with BMI but 176 
only after additional adjustment for HC and WC (model 3) with a HR per 1-SD increase in BMI of 1.15 177 
(95% CI: 1.03-1.27) (Figure S1). Associations with other measures of adiposity were non-significant 178 
although effect sizes were comparable, except for WHR (Figure 4). In addition, heterogeneity across 179 
studies was high for relative risks associated with WHR (I2 = 66%, P-heterogeneity=0.02) and did not change 180 
after excluding EPIC-Spain. 181 
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WHR was strongest and most consistently associated with ‘other obesity-related cancers’ (i.e. lower 182 
oesophagus, gastric cardia, liver, gallbladder, pancreas, endometrium, ovary, and kidney) with a HR per 183 
1-SD increase of 1.20 (95% CI: 1.04-1.38) (Figure 5). All other obesity-measures were non-significant. 184 
After mutual adjustment for adiposity measures, WC was also independently associated with ‘other 185 
obesity-related cancers’ (HR1-SD increase=1.15, 95% CI: 1.03-1.28) (Figure S1), while the association with 186 
WHR was marginally attenuated. 187 
All estimates for the association between the four adiposity measures by cancer site and cohort, 188 
and the pooled estimates for the different models are presented in Supplementary Table S2. 189 
  190 
Dose-response associations. After pooling all cohorts into one dataset, clear linear dose-response 191 
associations were found between all adiposity measures and ‘obesity-related cancers’, except for WHR 192 
(P-non-linear=0.02), where an increased cancer risk became apparent only at values >0.96 of the WHR 193 
(Supplementary Figure S2). For CRC, linear dose-response associations were observed for all four 194 
adiposity measures (Figure S2). For postmenopausal breast and ‘other obesity-related cancers’, dose-195 
response relationships were inconsistent across the four obesity measures and linearity largely statistically 196 
insignificant (Supplementary Figure S3). These findings were confirmed when analyzing BMI and WC 197 
in pre-defined categories (Supplementary Table S6) 198 
 199 
 Direct comparisons between anthropometric indicators. C-indices for WC, HC, and WHR were 200 
marginally and non-significantly lower than for BMI in predicting risk of ‘obesity-related cancers’, CRC, 201 
postmenopausal breast cancer (range of C-index differences to BMI: -0.01 to -0.02) and vice versa for 202 
‘other obesity-related cancers’(range of C-index differences to BMI: 0.02 to 0.03) (Table 2). Compared 203 
to a null model including all confounding variables but none of the four anthropometric indicators, adding 204 
BMI, WC, HC, and WHR separately or jointly resulted in virtually similar model fit as evaluated by AIC 205 
(Table 2). 206 
 207 
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Effect modification by sex, smoking, HT use, and weight status. After stratification by sex, the 208 
risks for ‘obesity-related cancers’ associated with BMI and WC were comparable between men and 209 
women (Supplementary Table S3). However, HC yielded higher risk estimates in women for ‘obesity-210 
related cancers’ and CRC. On the other hand, WHR yielded higher risk estimates in men compared to 211 
women for ‘obesity-related cancers’, CRC, and ‘other obesity-related cancers’. Some of these sex-specific 212 
differences became more pronounced or only apparent after mutual adjustment for adiposity measures 213 
(Model 3) (Table S3).  214 
Some variability in risk estimates was observed across smoking categories (Supplementary Table 215 
S4). However, formal tests for effect modification were only significant for associations between HC and 216 
CRC (P-interaction=0.02) with a significantly increased risk observed in never smokers (HR1-SD increase=1.33, 217 
95% CI: 1.16-1.54). 218 
For postmenopausal breast cancer, significantly increased risks were observed in women who 219 
never used HT, with similar effect sizes of ~20% increased risk per 1-SD increase of BMI, WC, and HC 220 
(P-interaction<0.001) (Model 2, Supplementary Table S5).  221 
No significant interactions between measures of body fat distribution (i.e. WC, HC, and WHR) and 222 
World Health Organizations’ BMI categories (normal weight: BMI <25 kg/m2, overweight: BMI ≥25 to 223 
<30 kg/m2, obesity: BMI ≥30 kg/m2) in relation to ‘obesity-related cancers’ and CRC or postmenopausal 224 
breast cancer were observed (data not shown). A borderline significant interaction for associations 225 
between WC and CRC across categories of BMI was observed (P-interaction=0.07) showing a significantly 226 
increased risk of CRC (HR1-SD increase=1.52, 95% CI: 1.20-1.92) in the overweight category.  227 
 228 
DISCUSSION 229 
In this pooled analysis of seven prospective cohort studies, we observed increased risks of 230 
‘obesity-related cancers’, overall and of CRC and postmenopausal breast cancer associated with 231 
equivalent increments of general adiposity (BMI) and measures of body fat distribution (WC, HC, and 232 
WHR). Relative risk estimates were comparable across the different adiposity indices. For 233 
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postmenopausal breast cancer, there was indication that increased risks were confined to women who 234 
never used HT. When mutually adjusting for all four anthropometric measures, which may be linked to 235 
different underlying biological mechanisms, BMI appeared to be an independent risk factor of ‘obesity-236 
related cancers’, CRC, and postmenopausal breast cancer. In contrast, WC and WHR appeared to be 237 
independent risk factors of ‘other obesity-related cancers’, which we could not analyse separately due to 238 
low number of cases. To our knowledge, this is the first study of older adults to comprehensively compare 239 
anthropometric measures of general adiposity and body fat distribution, to examine and quantify the 240 
respective independent effects of these measures and to examine the shape of the dose–response 241 
relationship for cancers known to be obesity-related. 242 
Our analysis does not corroborate the hypothesis that central adiposity is a superior predictor of 243 
CRC or postmenopausal breast cancer among older adults, as proposed by some previous studies (Pischon 244 
et al, 2006; Stolzenberg-Solomon et al, 2013; White et al, 2015). In contrast, and in line with our results, 245 
is an analysis of the NIH-AARP Diet and Health Study, where BMI, WC, and WHR were found to be 246 
equally discriminatory for colon cancer risk (Keimling et al, 2013). HC was not associated with risk of 247 
colon cancer in Keimling et al., while in our analysis HC virtually mirrored results for BMI, albeit effect 248 
sizes were slightly lower as compared to BMI. HC in disease models that do not account for BMI and/or 249 
WC is probably more indicative of general adiposity rather than an indicator of fat accumulation in the 250 
lower extremities reflected by a high correlation between HC and BMI (Pearson correlation ~0.8 in our 251 
data). Mutual adjustment of obesity indicators may reduce heterogeneity across studies as observed in our 252 
data. This could indicate that BMI does not capture general adiposity equally well in all White Caucasians 253 
and that holding WC and HC constant, improves the interpretation of BMI as a measure of general 254 
adiposity. 255 
Furthermore, in the Cancer Prevention Study-II Nutrition Cohort, positive associations between 256 
WC and BMI and postmenopausal breast cancer risk were reported, but only the association with BMI 257 
remained significant after mutual adjustment (Gaudet et al, 2014). 258 
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For postmenopausal breast cancer, early results from the Iowa Women Health Study suggested a 259 
statistically significant multiplicative interaction between BMI and WHR (Folsom et al, 2000). However, 260 
in subsequent reports that specifically tested interactions between BMI and indicators of central adiposity 261 
in relation to risk of CRC (Keimling et al, 2013) and breast cancer (Gaudet et al, 2015), no statistically 262 
significant associations were found. Our findings are in line with these more recent reports in that we did 263 
not find statistically significant multiplicative interactions between BMI and any of the three measures of 264 
body fat distribution.  265 
For most of the cancer sites that we grouped into ‘other obesity-related cancers’ due to the small 266 
number of cases, previous studies reported somewhat stronger associations with regard to measures of 267 
central adiposity as compared to BMI, which is in line with our findings. For example, in the meta-268 
analysis of Aune et al. on pancreatic cancer, WHR yielded an overall RR of 1.19 (95% CI: 1.09-1.31), 269 
while that for BMI was 1.10 (95% CI: 1.07-1.14) (Aune et al, 2012). Slightly stronger associations for 270 
WC and WHR, as compared to BMI, were also reported in the most recent WCRF/AICR pooled analyses 271 
for advanced prostate cancer (World Cancer Research Fund / American Institute for Cancer Research., 272 
2014). We were not able to include prostate cancer in our analysis because of lack of data by stage. 273 
In an analysis using data from the large EPIC prospective cohort, we reported previously that 274 
abdominal obesity, rather than general obesity, is a risk factor for the development of oesophageal 275 
adenocarcinoma and gastric cardia cancer (Steffen et al, 2015). In the prospective NIH-AARP cohort both 276 
overall adiposity (BMI) and abdominal adiposity (WC, WHR) were associated with a higher risk of 277 
oesophageal adenocarcinoma, but only BMI was associated with a higher risk of gastric cardia 278 
adenocarcinoma (O’Doherty et al, 2012). In an updated WCRF/AICR meta-analysis, BMI was more 279 
strongly associated with an increased risk of endometrial cancer compared to WC or WHR, although WC 280 
was also associated with an increased risk (Aune et al, 2015b). Similarly, an increased risk of ovarian 281 
cancer was reported with greater BMI and a marginally significant positive association with WC, but no 282 
association was found for HC or WHR (Aune et al, 2015a). We are not aware of studies investigating the 283 
role of body fat distribution and risk of cancers of the liver and gallbladder. The evidence with regard to 284 
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BMI was judged convincing for both of these cancer sites by the most recent WCRF/AICR pooled 285 
analyses (World Cancer Research Fund / American Institute for Cancer Research., 2015a, 2015b). For 286 
these last two cancer sites, further assessment of the impact of body fat distribution in future studies is 287 
warranted. 288 
Although WC and WHR (and HC as noted above) have been interpreted as measures of body fat 289 
distribution, they may well also be markers of general adiposity (Anderson et al, 2014). In the current 290 
study, we saw that these measures have associations with cancer that are similar to those for BMI, but 291 
mostly when used in separate models. However, few studies have conducted mutual adjustments between 292 
BMI and measures of body fat distribution to try to clarify their independent roles. This is a limitation, 293 
which needs further assessment in future studies because it may provide insight into the biologic 294 
mechanisms underlying observed associations between adiposity and cancer risk (Keimling et al, 2013). 295 
Ideally, for mutual adjustment of BMI and measures of body fat distribution, residuals of measures of 296 
WC and/or HC should be used in order to retain the interpretability of BMI as an indicator of general 297 
adiposity and to avoid potential problems of multi-collinearity. Otherwise, BMI is not easily interpretable 298 
or becomes an indicator of muscularity rather than adiposity (Hu, 2008). It is also of note that WC, HC, 299 
and WHR have larger measurement errors compared with measurement of BMI, which may affect the 300 
reliability of respective risk estimates and calls for additional caution when comparing results between 301 
these indicators. 302 
Links between greater adiposity and increased risk of many cancers are biologically plausible 303 
considering that obesity is related to a vast array of metabolic and physiological dysfunctions (Park et al, 304 
2014). A number of these altered processes have specifically been implicated in cancer development; 305 
notably (1) abnormalities of insulin resistance and the IGF-I system; described as the insulin-IGF-I-306 
insulin pathway, which may promote tumor development at many anatomic sites (Park et al, 2014; 307 
Renehan et al, 2015); 2) the impact of adiposity on the biosynthesis and bioavailability of endogenous sex 308 
steroids (e.g., oestradiol) which applies predominantly, but not exclusively, to postmenopausal breast, 309 
endometrial and ovarian cancers (Park et al, 2014; Renehan et al, 2015); our findings that obesity-310 
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associated risk of postmenopausal breast cancer was strongest in women, who never used HT support that 311 
hypothesis 3) obesity induced low-grade chronic systemic inflammation; and 4) alterations in the levels of 312 
adipocyte-derived factors, known as adipokines (Lee et al, 2015). All of these proposed pathways have 313 
been extensively investigated in mechanistic studies and tested in epidemiological settings. For example, 314 
adiponectin, one of the most abundant adipokines, has been shown to be a key mediator in the 315 
development of several types of obesity-related cancers including endometrial, breast, advanced prostate, 316 
CRC, renal, and pancreatic (Dalamaga et al, 2012). Unlike most of the other adipose tissue derived 317 
adipokines, serum adiponectin is reduced in obesity and correlates inversely with BMI, WC, HC, and 318 
WHR, independently of age and menopausal status (Dalamaga et al, 2012). Migrating adipose progenitor 319 
cells, which can be found in high concentration in white adipose tissue and may acquire a tumor-320 
promoting function, and the gut microbiome are two emerging mechanistic hypotheses linking obesity 321 
with cancer risk (Renehan et al, 2015).  322 
Our study has some limitations that may affect the interpretation of the results. Despite the 323 
pooling of seven cohorts, we were not able to compare adiposity measures across all anatomical cancer 324 
sites with strong evidence of an association with obesity because of low numbers of cases. These cancer 325 
sites were therefore combined in ‘other obesity-related cancers’. For this reason, we could not investigate 326 
whether one or several of these cancers may have driven the observed associations with WC and WHR. 327 
Also related to the low number of cases, we were not able to sub-divide CRC in its anatomical sub-sites – 328 
knowing that effects sizes are more pronounced for cancers of the colon as compared to the rectum 329 
(World Cancer Research Fund / American Institute for Cancer Research., 2011) – or to sub-divide breast 330 
cancer by receptor status. However, associations with BMI appear to be unrelated to receptor status in 331 
postmenopausal women who have never used HT (Renehan et al, 2015).  332 
Further limitations of our study are related to differences in study design between cohorts, 333 
including differences in length of follow-up and assessment of several covariates. In order to harmonize 334 
the data and variable definitions across cohorts, some covariates such as physical activity were only 335 
available in binary form (yes/no). Despite adjustment for the main confounding factors, namely smoking 336 
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and physical activity, we cannot rule out confounding by other unmeasured factors, most importantly 337 
reproductive factors and diet. As these were not consistently available from all cohorts, we were not able 338 
to take these into account in our analyses. However, we don’t expect risk estimates being noticeably 339 
confounded by diet as has been shown previously (Renehan et al, 2012). In the ESTHER study, BMI 340 
based on self-reported height and weight was the only adiposity indicator available. Although self-341 
reported BMI may grossly under-estimate prevalence of adiposity at the population level, ranking of 342 
individuals according to their BMI is less affected (Hu, 2008). Furthermore, study-specific risk estimates 343 
for ESTHER were consistent with the other cohorts and the summary estimates; excluding ESTHER from 344 
the meta-analysis had virtually no effect on the summary estimates (data not shown). Keeping ESTHER 345 
in our analysis also facilitates comparison of results with our companion paper, where we investigated the 346 
impact of overweight duration on obesity-related cancers (Arnold et al, 2016a). Finally, we did not a 347 
priori stratify our analysis by sex, mainly due to sample size considerations. However, in secondary 348 
analysis, largely similarly increased risks among men and women were observed for the investigated 349 
adiposity indicators (Table S3). 350 
Strengths of our study include the availability of harmonized individual-level data for the 351 
estimation of cohort-specific risk estimates. This allowed us to use the same exposure definitions, disease 352 
endpoints, and multivariate models in all included studies. Our investigation included only prospective 353 
cohort studies, which reduces the potential of biases that are often reason for concern in retrospective 354 
studies, e.g. recall and selection bias. Individuals within each of our cohorts were largely White 355 
Caucasian, which adds further validity to our results because the effects of a given WC in a White 356 
population may be very different to the same WC in an Asian or African-American population. However, 357 
these potential ethic differences need to be evaluated in future studies. Further, we explored and 358 
compared, to our knowledge for the first time in a pooled analysis of cohorts consisting of middle-aged 359 
and older adults, non-linear associations between BMI, WC, HC, and WHR for cancer-sites known to be 360 
adiposity-related. 361 
 362 
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Conclusions 363 
General adiposity as measured by BMI and body fat distribution as measured by WC, HC or 364 
WHR show comparable positive associations with obesity-related cancers combined, with CRC, and with 365 
postmenopausal breast cancer. For postmenopausal breast cancer there was evidence for effect 366 
modification by HT use which needs further exploration in other cohorts and populations. Avoiding 367 
abdominal fatness may also be important for specific cancer sites, but requires further investigation. 368 
Overall, our results underscore the importance of avoiding excess body fatness for cancer prevention 369 
irrespective of age and gender. 370 
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Text S1. Residual models. 
Residuals of waist circumference (WC), hip circumference (HC), and waist-to-hip ratio (WHR) were calculated with 
separate sex-specific linear regression models with body mass index (BMI) as the independent variable and WC, HC, and 
WHR as the dependent variables. These residuals are by definition independent of BMI and they facilitate model fitting 
and interpretation, where BMI and measures of central adiposity are included in the same model (Hu, 2008; Roswall et al, 
2014). In such models, BMI retains its interpretation as a measure of overall adiposity, while the residuals of WC and 
WHR retain their interpretation as measures of central adiposity that are independent of overall adiposity. On the other 
hand, relative risk associated with higher HC adjusted for BMI, WC, or both can be interpreted as an indicator of the 
combination of the bone structure of the pelvis (which is mostly genetically determined), gluteofemoral muscle mass, and 
gluteofemoral fat accumulation (Hu, 2008). 
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Table S1. Correlation matrix of anthropometric measures in the CHANCES cohorts. 
 
BMI WC HC WHR Height 
WC-
residuals 
HC-
residuals 
WHR-
residuals 
Men and Women 
        BMI 1.00 
       WC 0.75 1.00 
      HC 0.82 0.61 1.00 
     WHR 0.30 0.78 -0.02 1.00 
    Height -0.19 0.18 -0.15 0.34 1.00 
   WC-residuals 0.00 0.48 0.13 0.49 0.20 1.00 
  HC-residuals 0.00 0.12 0.51 -0.26 0.29 0.25 1.00 
 WHR-residuals 0.00 0.37 -0.21 0.64 0.00 0.77 -0.40 1.00 
Men 
        BMI 1.00 
       WC 0.85 1.00 
      HC 0.76 0.79 1.00 
     WHR 0.53 0.74 0.18 1.00 
    Height -0.16 0.00 0.09 -0.10 1.00 
   WC-residuals 0.00 0.51 0.24 0.55 0.34 1.00 
  HC-residuals 0.00 0.20 0.60 -0.33 0.42 0.40 1.00 
 WHR-residuals 0.00 0.34 -0.24 0.82 0.01 0.68 -0.40 1.00 
Women 
        BMI 1.00 
       WC 0.84 1.00 
      HC 0.87 0.78 1.00 
     WHR 0.41 0.75 0.17 1.00 
    Height -0.29 -0.21 -0.09 -0.23 1.00 
   WC-residuals 0.00 0.53 0.08 0.74 0.21 1.00 
  HC-residuals 0.00 0.09 0.48 -0.37 0.36 0.17 1.00 
 WHR-residuals 0.00 0.44 -0.20 0.90 -0.01 0.82 -0.41 1.00 
All values are Pearson correlation coefficients. 
Residuals of WC, HC, and WHR were calculated with separate sex-specific linear regression models with BMI as the 
independent variable and WC, HC, and WHR as the dependent variables in each of the three models; all models were 
adjusted for cohort. 
Abbreviations: BMI, body mass index; HC, hip circumference; WC, waist circumference; WHR, waist-to-hip ratio. 
 
 
 
 
 
Table S2. Hazard ratios (HR) and their 95% confidence intervals (CI) for the risk of incident cancer per 1 standard deviation (SD) increment of anthropometric measures for men and women, by cohort and cancer site 
 
Obesity-related cancersa  Breast cancer 
 
Colorectal cancer 
 
Other obesity-related cancersb 
 
Model 2 Model 3  Model 2 Model 3 
 
Model 2 Model 3 
 
Model 2 Model 3 
 HR 95% CI HR 95% CI  HR 95% CI HR 95% CI 
 
HR 95% CI HR 95% CI 
 
HR 95% CI HR 95% CI 
Body mass index  
EPIC_DK 1.06 0.96 1.16 1.06 0.96 1.16  0.98 0.84 1.13 1.00 0.87 1.17 
 
1.19 1.00 1.42 1.18 0.98 1.41 
 
1.05 0.87 1.26 1.03 0.85 1.24 
EPIC_GR 1.09 0.92 1.31 1.08 0.90 1.29  1.13 0.76 1.67 1.11 0.74 1.65 
 
1.23 0.88 1.71 1.22 0.88 1.70 
 
1.02 0.79 1.31 1.02 0.79 1.31 
EPIC_NL 1.17 1.03 1.33 1.16 1.02 1.33  1.32 1.09 1.60 1.32 1.08 1.60 
 
1.11 0.89 1.40 1.10 0.87 1.40 
 
1.01 0.76 1.34 0.97 0.73 1.29 
EPIC_SP 0.88 0.74 1.04 1.14 0.82 1.60  0.86 0.63 1.18 0.92 0.47 1.80 
 
0.84 0.64 1.11 0.86 0.65 1.15 
 
0.95 0.71 1.27 0.99 0.74 1.33 
ESTHERc 1.20 1.09 1.33 1.2 1.09 1.33  1.16 0.99 1.36 1.16 0.99 1.36 
 
1.17 0.97 1.43 1.18 0.97 1.43 
 
1.28 1.08 1.53 1.28 1.08 1.53 
PRIME Belfastd 1.50 1.08 2.07 1.51 1.09 2.10        
 
1.60 1.10 2.33 1.67 1.14 2.44 
 
1.12 0.58 2.17 1.14 0.59 2.23 
TROMSO 1.13 0.98 1.30 1.14 0.97 1.33  1.23 0.97 1.57 1.31 0.98 1.76 
 
1.23 1.00 1.52 1.19 0.95 1.49 
 
0.85 0.64 1.14 0.92 0.67 1.25 
Waist circumference  
EPIC_DK 1.06 0.95 1.17 1.00 0.90 1.11  0.94 0.80 1.10 0.91 0.77 1.06 
 
1.19 0.98 1.45 1.04 0.86 1.27 
 
1.12 0.92 1.36 1.14 0.94 1.39 
EPIC_GR 1.09 0.89 1.33 1.00 0.85 1.17  0.97 0.61 1.55 0.84 0.60 1.17 
 
1.20 0.83 1.74 0.97 0.72 1.31 
 
1.10 0.83 1.46 1.11 0.88 1.39 
EPIC_NL 1.17 1.00 1.36 0.99 0.86 1.15  1.26 1.00 1.58 0.91 0.73 1.14 
 
1.18 0.90 1.54 1.09 0.84 1.42 
 
1.04 0.76 1.42 1.05 0.77 1.42 
EPIC_SP 1.01 0.83 1.22 1.24 1.07 1.45  1.05 0.72 1.51 1.30 0.97 1.76 
 
0.94 0.69 1.28 1.21 0.94 1.55 
 
1.09 0.79 1.51 1.26 0.97 1.64 
ESTHERc              
 
      
 
      PRIME Belfastd 1.45 1.03 2.04 1.06 0.73 1.54     
    
1.52 1.02 2.26 0.94 0.61 1.45 
 
1.26 0.64 2.50 1.45 0.72 2.94 
TROMSO 1.28 1.08 1.51 1.23 1.04 1.46  1.51 1.09 2.10 1.28 0.93 1.76 
 
1.35 1.06 1.72 1.26 0.98 1.61 
 
1.01 0.72 1.41 1.15 0.84 1.59 
Hip circumference  
EPIC_DK 1.05 0.95 1.16 1.00 0.90 1.11  1.02 0.88 1.18 1.05 0.89 1.24 
 
1.16 0.96 1.40 0.98 0.80 1.20 
 
0.99 0.81 1.21 0.91 0.74 1.11 
EPIC_GR 1.22 1.02 1.46 1.24 1.04 1.48  1.23 0.84 1.81 1.25 0.84 1.85 
 
1.40 1.00 1.95 1.29 0.93 1.79 
 
1.15 0.89 1.49 1.22 0.94 1.58 
EPIC_NL 1.17 1.03 1.33 1.06 0.91 1.24  1.29 1.07 1.56 1.05 0.83 1.32 
 
1.12 0.90 1.40 1.07 0.82 1.41 
 
1.02 0.78 1.35 1.07 0.77 1.48 
EPIC_SP 0.86 0.73 1.02 0.87 0.74 1.03  0.92 0.68 1.23 0.96 0.70 1.33 
 
0.85 0.65 1.12 0.90 0.69 1.17 
 
0.86 0.65 1.13 0.77 0.58 1.02 
ESTHERc              
 
      
 
      PRIME Belfastd 1.36 0.95 1.95 0.90 0.62 1.29     
    
1.51 1.00 2.27 0.96 0.62 1.46 
 
1.00 0.48 2.11 0.73 0.37 1.44 
TROMSO 1.12 0.95 1.32 0.91 0.78 1.07  1.26 0.92 1.73 0.87 0.64 1.18 
 
1.20 0.93 1.54 0.92 0.73 1.17 
 
0.91 0.66 1.26 0.94 0.69 1.28 
Waist-to-hip ratio  
EPIC_DK 1.04 0.92 1.18 1.00 0.92 1.10  0.87 0.72 1.05 0.90 0.79 1.03 
 
1.16 0.92 1.46 1.04 0.88 1.23 
 
1.24 0.99 1.56 1.16 0.98 1.37 
EPIC_GR 0.91 0.72 1.15 0.93 0.80 1.09  0.72 0.42 1.25 0.79 0.55 1.13 
 
0.91 0.59 1.40 0.89 0.66 1.20 
 
1.01 0.73 1.39 1.02 0.82 1.27 
EPIC_NL 1.05 0.86 1.27 0.96 0.84 1.10  1.04 0.77 1.39 0.91 0.74 1.12 
 
1.12 0.80 1.58 1.02 0.80 1.30 
 
1.03 0.70 1.54 1.00 0.76 1.33 
EPIC_SP 1.33 1.05 1.68 1.25 1.07 1.45  1.33 0.83 2.12 1.23 0.91 1.67 
 
1.2 0.82 1.75 1.21 0.96 1.54 
 
1.52 1.02 2.25 1.31 1.01 1.7 
ESTHERc              
 
      
 
      PRIME Belfastd 1.52 0.97 2.38 1.12 0.79 1.58     
    
1.44 0.85 2.44 0.99 0.66 1.49 
 
1.74 0.73 4.15 1.52 0.81 2.85 
TROMSO 1.36 1.14 1.61 1.20 1.06 1.36   1.47 1.10 1.97 1.24 1.00 1.53  1.40 1.08 1.82 1.21 1.00 1.47  1.17 0.81 1.68 1.15 0.91 1.46 
All cohorts pooled 
BMI  1.11 1.06 1.17 1.12 1.02 1.24  1.11 1.01 1.21 1.10 0.99 1.23 
 
1.16 1.07 1.27 1.16 1.05 1.28 
 
1.06 0.97 1.16 0.99 0.89 1.11 
WC  1.12 1.04 1.19 1.06 1.00 1.13  1.07 0.96 1.19 0.96 0.86 1.08 
 
1.20 1.08 1.34 1.09 0.98 1.21 
 
1.08 0.96 1.22 1.14 1.02 1.27 
HC  1.08 1.01 1.14 1.01 0.94 1.07  1.11 1.00 1.24 1.05 0.94 1.18 
 
1.14 1.03 1.27 0.99 0.89 1.10 
 
0.98 0.88 1.10 0.96 0.85 1.07 
WHR 1.11 1.03 1.20 1.05 0.99 1.11   0.98 0.89 1.09 0.95 0.85 1.05   1.19 1.04 1.36 1.08 0.98 1.18   1.18 1.03 1.36 1.13 1.03 1.25 
a  First primary cancers of the breast (postmenopausal), colorectum, lower oesophagus, cardia stomach, liver, gallbladder, pancreas, endometrium, ovary, and kidney. 
b Same as all obesity-related cancers but excluding first primary cancers of the breast and of the colorectum; c  No data available on WC, HC, and WHR; d No breast cancer cases because men only. 
Model 2: stratified for age (1-y categories), and sex, and adjusted for daily smoking (never, former, current, missing), average alcohol consumption (g/d), education (primary or less, more than primary but less than college, 
college or university, missing), vigorous physical activity (yes, no, missing), recruitment year, and height; in the pooled analysis, models were additionally stratified by cohort. 
Model 3: as model 2, but models for BMI, WC, and HC were mutually adjusted using WC- and HC-residuals; the models for WHR were further adjusted for BMI using WHR-residuals. 
Note: Results of Model 1 are not shown due to space limitations, but results were similar to Model 2. 
Abbreviations: BMI, body mass index; DK, Denmark; GR, Greece; HC, hip circumference; NL, the Netherlands; SP, Spain; WC, waist circumference; WHR, waist-to-hip ratio. 
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Table S3. Hazard ratios (HR) and their 95% confidence intervals (CI) for the risk of incident cancer per 1-standard deviation (SD) increment of 
anthropometric measures, by sex and cancer site 
  
Model 1     Model 2     Model 3 
 
Cases HR 95% CI   Cases HR 95% CI   Cases HR 95% CI 
    MEN   
Body mass index (1 SD=3.6 kg/m2) 
 Obesity-related cancersa 524 1.13 1.04 1.24 
 
524 1.14 1.05 1.25 
 
389 1.17 1.00 1.38 
 Colorectal cancer 318 1.13 1.01 1.26 
 
318 1.16 1.01 1.33 
 
243 1.15 0.98 1.34 
 Other obesity-related cancersb 206 1.14 0.99 1.31 
 
206 1.15 1.01 1.33 
 
146 1.10 0.85 1.43 
Waist circumference (1 SD=10.1 cm) 
 Obesity-related cancersa 389 1.15 1.03 1.28 
 
389 1.15 1.03 1.28 
 
389 1.14 1.01 1.27 
 Colorectal cancer 243 1.13 0.98 1.29 
 
243 1.15 0.98 1.36 
 
243 1.06 0.90 1.25 
 Other obesity-related cancersb 146 1.20 1.01 1.42 
 
146 1.19 1.00 1.42 
 
146 1.31 1.09 1.56 
Hip circumference (1 SD=7.2 cm) 
 Obesity-related cancersa 389 1.02 0.91 1.14 
 
389 1.04 0.93 1.17 
 
389 0.90 0.80 1.02 
 Colorectal cancer 243 1.04 0.90 1.20 
 
243 1.07 0.89 1.28 
 
243 0.91 0.78 1.06 
 Other obesity-related cancersb 146 1.01 0.84 1.21 
 
146 1.03 0.85 1.24 
 
146 0.90 0.74 1.09 
Waist-to-hip ratio (1 SD=0.06) 
 Obesity-related cancersa 389 1.20 1.09 1.33 
 
389 1.19 1.07 1.31 
 
389 1.15 1.04 1.27 
 Colorectal cancer 243 1.18 1.03 1.35 
 
243 1.21 0.99 1.47 
 
243 1.09 0.94 1.27 
 Other obesity-related cancersb 146 1.28 1.10 1.50 
 
146 1.26 1.07 1.48 
 
146 1.25 1.08 1.45 
    WOMEN   
Body mass index (1 SD=4.6 kg/m2) 
Obesity-related cancersa 1132 1.08 1.01 1.15 
 
1132 1.10 1.03 1.17 
 
867 1.07 1.00 1.16 
 Colorectal cancer 273 1.17 1.03 1.32 
 
273 1.17 1.04 1.32 
 
222 1.15 1.00 1.31 
 Breast cancer 555 1.09 0.99 1.19 
 
555 1.12 1.02 1.22 
 
409 1.10 0.99 1.23 
Other obesity-related cancersb 304 0.99 0.87 1.12 
 
304 1.00 0.88 1.13 
 
236 1.16 0.89 1.50 
Waist circumference (1 SD=11.6 cm) 
Obesity-related cancersa 867 1.08 1.01 1.16 
 
867 1.09 1.01 1.17 
 
867 1.04 0.96 1.12 
 Colorectal cancer 222 1.23 1.07 1.42 
 
222 1.24 1.07 1.44 
 
222 1.13 0.98 1.29 
 Breast cancer 409 1.05 0.95 1.17 
 
409 1.07 0.96 1.19 
 
409 0.96 0.86 1.08 
Other obesity-related cancersb 236 1.01 0.87 1.16 
 
236 1.00 0.87 1.16 
 
236 1.07 0.93 1.23 
Hip circumference (1 SD=9.3 cm) 
Obesity-related cancersa 867 1.08 1.00 1.16 
 
867 1.09 1.01 1.17 
 
867 1.04 0.96 1.13 
 Colorectal cancer 222 1.20 1.04 1.38 
 
222 1.18 1.04 1.34 
 
222 1.08 0.93 1.25 
 Breast cancer 409 1.09 0.99 1.21 
 
409 1.11 1.00 1.24 
 
409 1.05 0.94 1.18 
Other obesity-related cancersb 236 0.95 0.82 1.09 
 
236 0.96 0.83 1.10 
 
236 0.98 0.84 1.13 
Waist-to-hip ratio (1 SD=0.07) 
Obesity-related cancersa 867 1.04 0.97 1.12 
 
867 1.04 0.97 1.12 
 
867 1.01 0.94 1.09 
 Colorectal cancer 222 1.16 1.00 1.35 
 
222 1.17 0.98 1.40 
 
222 1.06 0.94 1.20 
 Breast cancer 409 0.98 0.89 1.09 
 
409 0.98 0.9 1.1 
 
409 0.95 0.85 1.05 
Other obesity-related cancersb 236 1.08 0.94 1.23 
 
236 1.06 0.9 1.2 
 
236 1.07 0.94 1.22 
a First primary cancers of the breast (postmenopausal), colorectum, lower oesophagus, cardia stomach, liver, gallbladder, pancreas, endometrium, ovary, and 
kidney.  
b Same as all obesity-related cancers but excluding first primary cancers of the breast and of the colorectum. 
Model 1: stratified for age (1-y categories) and cohort (pooled analysis), and adjusted for height. 
Model 2: as model 1 and further adjusted for daily smoking (never, former, current, missing), average alcohol consumption (g/d), education (primary or less, more 
than primary but less than college, college or university, missing), vigorous physical activity (yes, no, missing), and recruitment year. 
Model 3: as model 2, but models for BMI, WC, and HC were mutually adjusted using WC- and HC-residuals; the model for WHR was further adjusted for BMI using 
WHR-residuals. 
Notes: no formal test for interaction by sex was performed because Cox models were stratified by sex to meet the proportionality of hazards assumption; SDs for 
anthropometric measure shown within brackets are the pooled average across all 7 cohorts by sex. 
 
 
Table S4. Hazard ratios (HR) and their 95% confidence intervals (CI) for the risk of incident cancer per 1 standard deviation (SD) increment of anthropometric measures, by smoking status and cancer site 
 Obesity-related cancers
a Breast cancer Colorectal cancer Other obesity-related cancersb 
 Model 2 Model 3 Model 2 Model 3 Model 2 Model 3 Model 2 Model 3 
 HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Body mass index (1 SD=4.2 kg/m2) 
Current daily smoker 1.09 0.98 - 1.21 1.06 0.94 - 1.19 1.26 1.03 - 1.55 1.28 1.00 - 1.63 1.11 0.93 - 1.32 1.03 0.85 - 1.25 0.92 0.75 - 1.13 0.93 0.76 - 1.14 
Former daily smoker 1.10 1.00 - 1.20 1.08 0.97 - 1.21 1.02 0.85 - 1.22 1.05 0.85 - 1.28 1.17 1.01 - 1.35 1.16 0.97 - 1.38 1.13 0.94 - 1.37 1.08 0.87 - 1.33 
Never daily smoker 1.12 1.04 - 1.20 1.08 1.00 - 1.18 1.11 0.99 - 1.25 1.08 0.93 - 1.25 1.20 1.05 - 1.37 1.23 1.06 - 1.43 1.10 0.95 - 1.28 0.98 0.84 - 1.16 
Waist circumference (1 SD=12.1 cm) 
Current daily smoker 1.14 1.02 - 1.28 1.07 0.95 - 1.20 1.13 0.89 - 1.44 0.88 0.68 - 1.13 1.19 0.99 - 1.43 1.19 0.97 - 1.44 1.05 0.86 - 1.27 1.12 0.91 - 1.37 
Former daily smoker 1.09 0.98 - 1.22 1.00 0.89 - 1.11 0.97 0.79 - 1.19 0.87 0.72 - 1.07 1.14 0.96 - 1.35 0.94 0.79 - 1.12 1.23 1.01 - 1.50 1.25 1.03 - 1.53 
Never daily smoker 1.11 1.02 - 1.22 1.10 1.01 - 1.19 1.10 0.95 - 1.27 1.05 0.90 - 1.21 1.27 1.08 - 1.49 1.16 1.00 - 1.35 1.02 0.86 - 1.21 1.10 0.94 - 1.28 
Hip circumference (1 SD= 8.6 cm) 
Current daily smoker 0.99 0.87 - 1.12 0.93 0.83 - 1.04 1.26 0.99 - 1.60 1.07 0.84 - 1.36 0.91 0.74 - 1.12 0.88 0.73 - 1.05 0.89 0.72 - 1.10 0.89 0.73 - 1.08 
Former daily smoker 1.04 0.93 - 1.16 0.95 0.86 - 1.06 1.02 0.84 - 1.24 0.97 0.80 - 1.17 1.08 0.90 - 1.29 0.92 0.78 - 1.09 1.03 0.84 1.28 0.95 0.78 - 1.16 
Never daily smoker 1.14 1.05 - 1.24 1.09 0.99 - 1.19 1.12 0.97 - 1.29 1.10 0.95 - 1.27 1.33 1.16 - 1.54 1.14 0.97 - 1.33 1.00 0.85 - 1.17 1.00 0.85. - 1.18 
Waist-to-hip ratio (1 SD=0.1) 
Current daily smoker 1.22 1.08 - 1.37 1.09 0.99 - 1.21 0.96 0.76 - 1.21 0.87 0.68 - 1.10 1.36 1.13 - 1.64 1.22 1.04 - 1.42 1.19 0.98 - 1.46 1.14 0.96 - 1.35 
Former daily smoker 1.11 0.99 - 1.25 1.03 0.93 - 1.14 0.94 0.77 - 1.13 0.91 0.76 - 1.10 1.15 0.95 - 1.38 0.98 0.83 - 1.17 1.36 1.10 - 1.68 1.25 1.04 - 1.50 
Never daily smoker 1.04 0.94 - 1.16 1.04 0.96 - 1.13 1.03 0.89 - 1.19 1.00 0.87 - 1.16 1.08 0.89 - 1.29 1.05 0.90 - 1.22 1.08 0.89 - 1.32 1.07 0.92 - 1.25 
a First primary cancers of the breast (postmenopausal), colorectum, lower oesophagus, cardia stomach, liver, gallbladder, pancreas, endometrium, ovary, and kidney.  
b Same as all obesity-related cancers but excluding first primary cancers of the breast and of the colorectum. 
Model 2: stratified for age (1-y categories), sex, and cohort (pooled analysis), and adjusted for daily smoking (never, former, current, missing), average alcohol consumption (g/d), education (primary or less, more than primary but less than 
college, college or university, missing), vigorous physical activity (yes, no, missing), recruitment year, and height. 
Model 3: as model 2, but models for BMI, WC, and HC were mutually adjusted using WC- and HC-residuals; the models for WHR were further adjusted for BMI using WHR-residuals. 
All P-values for interaction (LR test) >0.10, except for HC vs. CRC in model 2 (P=0.02). 
Note: SDs for anthropometric measure shown within brackets are the pooled average across all 7 cohorts and men and women combined. 
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Table S5. Hazard ratios (HR) and their 95% confidence intervals (CI) for the risk 
of incident breast cancer (postmenopausal) per 1 standard deviation (SD) 
increment of anthropometric measures, by hormone therapy (HT) use 
 
 Breast cancer (postmenopausal) 
 
 Model 2 
 
Model 3 
 
Cases HR 95% CI 
 
HR 95% CI 
Body mass index (1 SD=4.6 kg/m2) 
never HT user 263 1.22 1.08 - 1.38 
 
1.28 1.11 - 1.47 
ever HT user 245 0.99 0.86 - 1.14 
 
0.91 0.76 - 1.10 
unknown 47 1.26 0.95 - 1.67 
 
1.02 0.73 - 1.43 
Waist circumference (1 SD=11.6 cm) 
never HT user 205 1.21 1.05 - 1.40 
 
0.95 0.81 - 1.11 
ever HT user 167 0.93 0.78 - 1.11 
 
0.99 0.83 - 1.18 
unknown 37 1.00 0.71 - 1.41 
 
1.01 0.75 - 1.35 
Hip circumference (1 SD=9.3 cm) 
never HT user 205 1.24 1.08 - 1.42 
 
1.00 0.86 - 1.16 
ever HT user 167 0.96 0.80 - 1.14 
 
1.08 0.91 - 1.28 
unknown 37 1.13 0.82 - 1.55 
 
1.25 0.92 - 1.68 
Waist-to-hip ratio (1 SD=0.07) 
never HT user 205 1.06 0.91 - 1.23 
 
0.96 0.83 - 1.12 
ever HT user 167 0.94 0.80 - 1.11 
 
0.95 0.81 - 1.11 
unknown 37 0.89 0.64 - 1.24 
 
0.91 0.67 - 1.24 
Model 2: stratified for age (1-y categories) and cohort (pooled analysis), and adjusted for 
daily smoking (never, former, current, missing), average alcohol consumption (g/d), 
education (primary or less, more than primary but less than college, college or university, 
missing), vigorous physical activity (yes, no, missing), recruitment year, and height. 
Model 3: as model 2, but models for BMI, WC, and HC mutually adjusted using WC- and 
HC-residuals; the models for WHR were further adjusted for BMI using WHR-residuals. 
All P-values for interaction (LR test) <0.001. 
Note: SDs for anthropometric measure shown within brackets are the pooled average 
across all cohorts in women. 
 
 
Table S6. Hazard ratios (HR) and their 95% confidence intervals (CI) for the risk of incident cancer per categories of Body mass index (BMI) and waist circumference (WC), by sex 
  Obesity-related cancersa Breast cancer Colorectal cancer Other obesity-related cancersb 
 n Cases HR 95 % CI p-trend Cases HR 95 % CI p-trend Cases HR 95 % CI p-trend Cases HR 95 % CI p-trend 
   MEN 
BMI categories   
<25 kg/m2  5,192 127 1 (ref.)       81 1 (ref.)   46 1 (ref.)   
 25-29.9 kg/m2 9,733 285 1.25 1.01 - 1.55      173 1.23 0.94 - 1.62  112 1.29 0.91 - 1.83  
>30 kg/m2 3,743 112 1.36 1.04 - 1.78 0.023     64 1.33 0.94 - 1.88 0.113 48 1.44 0.94 - 2.19 0.095 
WC categories    
<102 cm 9,677 254 1 (ref.)       170 1 (ref.)   84 1 (ref.)   
>102 cm 4,348 135 1.25 1.00 - 1.57      73 1.07 0.80 - 1.44  62 1.60 1.13 - 2.28  
   WOMEN 
BMI categories   
<25 kg/m2 8,422 418 1 (ref.)   207 1 (ref.)   95 1 (ref.)   116 1 (ref.)   
25-29.9 kg/m2 9,888 442 1.02 0.89 - 1.17  224 1.11 0.92 - 1.35  102 1.02 0.77 - 1.36  116 0.86 0.66 - 1.13  
>30 kg/m2 6,441 272 1.17 1.00 - 1.39 0.057 124 1.22 0.96 - 1.55 0.098 76 1.44 1.04 - 2.00 0.029 72 0.90 0.65 - 1.24 0.517 
WC categories   
<88 cm 10,482 502 1 (ref.)   249 1 (ref.)   119 1 (ref.)   134 1 (ref.)   
>88 cm 8,566 365 1.14 0.99 - 1.32  160 1.13 0.91 - 1.39  103 1.33 1.00 - 1.76  102 1.01 0.77 - 1.34  
a First primary cancers of the breast (postmenopausal), colorectum, lower oesophagus, cardia stomach, liver, gallbladder, pancreas, endometrium, ovary, and kidney.  
b Same as all obesity-related cancers but excluding first primary cancers of the breast and of the colorectum.  
Model 2: stratified for age (1-y categories) and cohort (pooled analysis), and adjusted for daily smoking (never, former, current, missing), average alcohol consumption (g/d), education (primary or less, more than primary but less than 
college, college or university, missing), vigorous physical activity (yes, no, missing), recruitment year, and height. 
Notes: BMI categories according to World Health Organization; category <25 kg/m2 includes 47 men and 169 women with a BMI <18.5 kg/m2, respectively; WC categories according to American Heart Association/National Heart, Lung 
and Blood Institute.  
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Figure S1. Random-effects meta-analysis of the association of different obesity-indicators per 1 standard deviation (SD) increment with (A) ‘obesity-related cancers’a, (B) colorectal cancer, (C) 
postmenopausal breast cancer, and (D) ‘other obesity-related cancers’b after mutual adjustment for each obesity-indicator. 
a First primary cancers of the breast (postmenopausal), colorectum, lower oesophagus, cardia stomach, liver, gallbladder, pancreas, endometrium, ovary, and kidney.  
b Same as all obesity-related cancers but excluding first primary cancers of the breast and of the colorectum. 
Model 3: stratified for age (1-y categories) and sex, and adjusted for daily smoking (never, former, current, missing), average alcohol consumption (g/d), education (primary or less, more than primary but less than college, college or university, missing), 
vigorous physical activity (yes, no, missing), recruitment year, and height; and models for BMI, WC, and HC were mutually adjusted using WC- and HC-residuals; and the models for WHR were further adjusted for BMI using WHR-residuals. 
Abbreviations: BMI, body mass index; DK, Denmark; GR, Greece; HC, hip circumference; NL, the Netherlands; SP, Spain; WC, waist circumference; WHR, waist-to-hip ratio. 
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Figure S1 continued. Random-effects meta-analysis of the association of different obesity-indicators per 1 standard deviation (SD) increment with (A) ‘obesity-related cancers’a, (B) colorectal cancer, 
(C) postmenopausal breast cancer, and (D) ‘other obesity-related cancers’b after mutual adjustment for each obesity-indicator. 
a First primary cancers of the breast (postmenopausal), colorectum, lower oesophagus, cardia stomach, liver, gallbladder, pancreas, endometrium, ovary, and kidney.  
b Same as all obesity-related cancers but excluding first primary cancers of the breast and of the colorectum. 
Model 3: stratified for age (1-y categories) and sex, and adjusted for daily smoking (never, former, current, missing), average alcohol consumption (g/d), education (primary or less, more than primary but less than college, college or university, missing), 
vigorous physical activity (yes, no, missing), recruitment year, and height; and models for BMI, WC, and HC were mutually adjusted using WC- and HC-residuals; and the models for WHR were further adjusted for BMI using WHR-residuals. 
Abbreviations: BMI, body mass index; DK, Denmark; GR, Greece; HC, hip circumference; NL, the Netherlands; SP, Spain; WC, waist circumference; WHR, waist-to-hip ratio. 
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Figure S2. Association of different obesity indicators with ‘obesity-related cancers’a and with colorectal cancer, allowing for non-linear effects. 
a First primary cancers of the breast (postmenopausal), colorectum, lower oesophagus, cardia stomach, liver, gallbladder, pancreas, endometrium, ovary, and kidney.  
The figures show a 3-knot restricted cubic spline model at Harrell’s default percentiles (i.e. 10th [reference point], 50th, and 90th) allowing for non-linear effects and are stratified for age (1-y 
categories) and cohort (pooled analysis), and adjusted for daily smoking (never, former, current, missing), average alcohol consumption (g/d), education (primary or less, more than 
primary but less than college, college or university, missing), vigorous physical activity (yes, no, missing), recruitment year, and height. P-values are from Wald-test evaluating the linearity 
hypothesis.
   
 
Figure S3. Association of different obesity indicators with postmenopausal breast cancer and with ‘other obesity-related cancers’a, allowing for non-
linear effects. 
a First primary cancers of the lower oesophagus, cardia stomach, liver, gallbladder, pancreas, endometrium, ovary, and kidney. 
The figures show a 3-knot restricted cubic spline model at Harrell’s default percentiles (i.e. 10th [reference point], 50th, and 90th) allowing for non-linear effects and are stratified for age (1-y 
categories) and cohort (pooled analysis), and adjusted for daily smoking (never, former, current, missing), average alcohol consumption (g/d), education (primary or less, more than 
primary but less than college, college or university, missing), vigorous physical activity (yes, no, missing), recruitment year, and height. P-values are from Wald-test evaluating the linearity 
hypothesis. 
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Table 1. Study and participants characteristics by cohort in the CHANCES consortium of middle-aged and older adults 
 EPIC Elderly Germany 
(ESTHER) 
Northern Ireland 
(PRIME Belfast) 
Norway 
(Tromsø) Characteristic Denmark Greece Netherlands Spain 
        Recruitment year, range 1993-1997 1994-1999 1993-1997 1992-1996 2000-2003 1991-1994 1994-1995 
               Age at entry, years (SD) 62.5 1.5 66.9 4.4 64.3 2.7 62.5 1.7 61.9 6.6 54.2 2.8 59.4 6.9 
               Sex                
   Men, n (%) 5072 46.4 2882 40.1 210 4.9 1949 42.5 3849 44.9 1944 100 2762 46.7 
   Women, n (%) 5853 53.6 4299 59.9 4085 95.1 2635 57.5 4728 55.1 0 0 3151 53.3 
               Education               
   Low, n (%) 4193 38.4 6539 91.1 1303 30.3 3927 85.7 6197 72.3 15 0.8 3033 51.3 
   Medium, n (%)  4889 44.8 398 5.5 2451 57.1 320 7.0 1757 20.5 1677 86.3 1726 29.2 
   High, n (%)  1827 16.7 220 3.1 521 12.1 287 6.3 415 4.8 252 13.0 1118 18.9 
   Unknown, n (%) 16 0.2 24 0.3 20 0.5 50 1.1 208 2.4 0 0.0 36 0.6 
               BMI at baseline, kg/m2 (SD) 26.2 3.9 29.3 4.3 25.8 3.9 29.5 4.0 27.6 4.2 26.1 3.2 26.1 3.7 
   Underweight, n (%) 62 0.6 19 0.3 46 1.1 4 0.1 33 0.4 8 0.4 44 0.7 
   Normal weight, n (%) 4421 40.5 1114 15.5 1947 45.3 493 10.8 2323 27.1 723 37.2 2377 40.2 
   Overweight, n (%) 4861 44.5 3125 43.5 1745 40.6 2167 47.3 4064 47.4 998 51.3 2661 45.0 
   Obese, n (%)  1581 14.5 2923 40.7 557 13.0 1920 41.9 2157 25.2 215 11.1 831 14.1 
        WC at baseline, cm (SD) 89.1 12.4 95.9 11.4 84.2 10.3 97.1 10.7 - - 90.9 9.1 90.1 10.9 
        HC at baseline, cm (SD) 101.2 7.8 106.3 9.1 103.8 8.3 107.9 8.5 - - 96.8 6.4 103.5 7.3 
        WHR at baseline, ratio (SD) 0.88 0.10 0.90 0.09 0.81 0.07 0.90 0.08 - - 0.94 0.05 0.87 0.08 
Height at baseline, cm (SD) 168.8 8.8 158.2 8.7 163.8 6.5 159.5 8.6 167.3 8.4 174.2 6.8 168.2 9.4 
        Vigorous physical activity                
   No, n (%) 1752 16.0 5566 77.5 1669 38.9 4311 94 4853 56.6 1689 86.9 3528 59.7 
   Yes, n (%) 5135 47.0 1506 21.0 2480 57.7 242 5.3 3704 43.2 255 13.1 2324 39.3 
   Unknown, n (%) 4038 37.0 109 1.5 146 3.4 31 0.7 20 0.2 0 0.0 61 1.0 
               Alcohol intake, grams/d (SD) 19.0 19.8 7.5 15.4 7.8 11.9 13.0 22.2 6.8 9.4 20.3 30.4 3.6 5.1 
               Smoking status               
   Never daily smoker, n (%) 3625 33.2 4891 68.1 2052 47.8 3109 67.8 4191 48.9 792 40.7 1950 33.0 
   Former daily smoker, n (%) 4078 37.3 1285 17.9 1532 35.7 732 16.0 2772 32.3 637 32.8 2127 36.0 
   Current daily smoker, n (%) 3201 29.3 805 11.2 694 16.2 740 16.1 1389 16.2 491 25.3 1831 30.9 
   Unknown, n (%) 21 0.2 200 2.8 17 0.4 3 0.1 255 2.6 24 1.2 5 0.1 
               Median follow-up time, years 11.9  11.5  13.2  13.4  10.5  18.0  15.9  
               N cancers cases               
   N all obesity-relateda 465  127  250  164  352  56  242  
   N breast cancer (age>50, women only) 193  22  109  42  125  -  64  
   N colorectal cancer 141  39  80  66  111  41  113  
   N other obesity-relatedb 131  66  61  56  116  15  65  
a First primary cancers of the breast (postmenopausal), colorectum, lower oesophagus, cardia stomach, liver, gallbladder, pancreas, endometrium, ovary, and kidney. 
b Same as all obesity-related cancers but excluding first primary cancers of the breast and of the colorectum. 
Note: All values are means, except when stated otherwise. 
Abbreviations: BMI, body mass index; HC, hip circumference; WC, waist circumference; WHR, waist-to-hip ratio. 
 
 
Table 2. Changes in risk discrimination for the risk of incident cancer in men and women combined after addition of anthropometric indicators to the null model 
 Null model BMI WC HC WHR BMI + WC + HC 
 Estimate 95% CI Estimate 95% CI Estimate 95% CI Estimate 95% CI Estimate 95% CI Estimate 95% CI 
Obesity-related 
cancersa 
                 
AIC 15826.6  15823.6   15820.6   15823.7   15823.4   15823.1   
C-index 0.688 0.676 - 0.699 0.687 0.675 - 0.698 0.663 0.649 - 0.677 0.663 0.650 - 0.677 0.664 0.651 - 0.678 0.663 0.650 - 0.677 
Colorectal cancer                   
AIC 5678.8   5672.8   5670.2   5674.8   5674.0   5673.5   
C-index 0.688 0.667 - 0.709 0.689 0.668 - 0.711 0.680 0.655 - 0.704 0.679 0.655 - 0.704 0.681 0.657 - 0.706 0.681 0.656 - 0.705 
Breast cancerb                   
AIC 5031.2   5030.3   5031.9   5032.0   5033.1   5032.9   
C-index 0.824 0.813 - 0.836 0.823 0.812 - 0.835 0.801 0.787 - 0.815 0.802 0.788 - 0.816 0.803 0.789 - 0.817 0.801 0.787 - 0.815 
Other obesity-
related cancersc 
                  
AIC 4780.7   4782.7   4781.4   4782.2   4777.0   4780.6   
C-index 0.588 0.561 - 0.615 0.587 0.559 - 0.614 0.605 0.573 - 0.637 0.605 0.574 - 0.637 0.612 0.581 - 0.643 0.618 0.587 - 0.648 
a First primary cancers of the breast (postmenopausal), colorectum, lower oesophagus, cardia stomach, liver, gallbladder, pancreas, endometrium, ovary, and kidney. 
b Women only. 
c Same as all obesity-related cancers but excluding first primary cancers of the breast and of the colorectum. 
Note: Null model included sex, age, daily smoking (never, former, current, missing), average alcohol consumption (g/d), education (primary or less, more than primary but less than college, college 
or university, missing), vigorous physical activity (yes, no, missing), recruitment year, and height. 
Abbreviations: AIC, Akaike Information Criterion; BMI, body mass index; CI, confidence interval; HC, hip circumference; WC, waist circumference; WHR, waist-to-hip ratio. 
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Figure 1. Flowchart of participant inclusion. 
 
Figure 2. Random-effects meta-analysis of the association of different obesity indicators per 1 standard 
deviation (SD) increment with ‘obesity-related cancers’a. 
a First primary cancers of the breast (postmenopausal), colorectum, lower oesophagus, cardia stomach, liver, gallbladder, 
pancreas, endometrium, ovary, and kidney.  
Adjustments were made for sex, age at entry, daily smoking (never, former, current, missing), average alcohol consumption 
(g/d), education (primary or less, more than primary but less than college, college or university, missing), vigorous physical 
activity (yes, no, missing), recruitment year, and height. 
Abbreviations: BMI, body mass index; DK, Denmark; GR, Greece; HC, hip circumference; NL, the Netherlands; SP, Spain; 
WC, waist circumference; WHR, waist-to-hip ratio. 
 
Figure 3. Random-effects meta-analysis of the association of different obesity indicators per 1 standard 
deviation (SD) increment with colorectal cancer. 
Adjustments were made for sex, age at entry, daily smoking (never, former, current, missing), average alcohol consumption 
(g/d), education (primary or less, more than primary but less than college, college or university, missing), vigorous physical 
activity (yes, no, missing), recruitment year, and height. 
Abbreviations: BMI, body mass index; DK, Denmark; GR, Greece; HC, hip circumference; NL, the Netherlands; SP, Spain; 
WC, waist circumference; WHR, waist-to-hip ratio. 
 
Figure 4. Random-effects meta-analysis of the association of different obesity indicators per 1 standard 
deviation (SD) increment with postmenopausal breast cancer. 
Adjustments were made for sex, age at entry, daily smoking (never, former, current, missing), average alcohol consumption 
(g/d), education (primary or less, more than primary but less than college, college or university, missing), vigorous physical 
activity (yes, no, missing), recruitment year, and height. 
Abbreviations: BMI, body mass index; DK, Denmark; GR, Greece; HC, hip circumference; NL, the Netherlands; SP, Spain; 
WC, waist circumference; WHR, waist-to-hip ratio. 
 
Figure 5. Random-effects meta-analysis of the association of different obesity indicators per 1 standard 
deviation (SD) increment with ‘other obesity-related cancers’a. 
a First primary cancers of the lower oesophagus, cardia stomach, liver, gallbladder, pancreas, endometrium, ovary, and kidney. 
Adjustments were made for sex, age at entry, daily smoking (never, former, current, missing), average alcohol consumption 
(g/d), education (primary or less, more than primary but less than college, college or university, missing), vigorous physical 
activity (yes, no, missing), recruitment year, and height. 
Abbreviations: BMI, body mass index; DK, Denmark; GR, Greece; HC, hip circumference; NL, the Netherlands; SP, Spain; 
WC, waist circumference; WHR, waist-to-hip ratio. 
 
 
 
